Molecular Devices Announces the Introduction of the IMAP(TM) Progressive Binding System and Nine New Substrates
November 06 2003 - 12:22PM
PR Newswire (US)
Molecular Devices Announces the Introduction of the IMAP(TM)
Progressive Binding System and Nine New Substrates SUNNYVALE,
Calif., Nov. 6 /PRNewswire-FirstCall/ -- Molecular Devices
Corporation , a leader in innovative solutions for drug discovery
and life sciences research, today announced the launch of the most
recent additions to its IMAP(TM) platform, the IMAP Progressive
Binding System and nine new peptide substrates. With the IMAP
Progressive Binding System, researchers can achieve enhanced
performance for virtually all kinases, phosphatases and
phosphodiesterases by addressing key parameters, such as substrate
limitations, ATP concentrations and background levels. The nine new
peptides added to Molecular Devices' growing line of validated
peptides further support IMAP as a complete systems approach for
assaying enzyme activity. Molecular Devices' IMAP technology is
rapidly becoming the established assay format to screen for kinase
and phosphatase activity because it does not rely on radioactivity
or antibodies. The new binding system and growing list of validated
substrates further enable the end user to develop assays for
uncommon or proprietary enzymes with the same ease of
miniaturization and low cost-per-well that IMAP users have come to
expect. "Kinases and phosphatases are screened at all major
pharmaceutical companies, and we believe that IMAP is becoming the
preferred screening platform. Molecular Devices will continue to
add key components that provide our customers with the flexibility
required to address this important yet diverse class of drug
targets," stated Stephen Oldfield, Ph.D. and Vice President of
Worldwide Marketing at Molecular Devices. "By exploiting the
ratiometric format inherent in fluorescence polarization, IMAP
leverages Molecular Devices' line of Analyst(R) instruments which
are known for setting industry standards in FP detection."
Molecular Devices Corporation is a leading supplier of
high-performance bioanalytical measurement systems that accelerate
and improve drug discovery and other life sciences research. The
Company's systems and consumables enable pharmaceutical and
biotechnology companies to leverage advances in genomics,
proteomics and combinatorial chemistry by facilitating the high-
throughput and cost-effective identification and evaluation of drug
candidates. The Company's solutions are based on its advanced core
technologies that integrate its expertise in engineering, molecular
and cell biology and chemistry. Molecular Devices enables its
customers to improve research productivity and effectiveness, which
ultimately accelerates the complex process of discovering and
developing new drugs. This press release contains "forward-looking"
statements, including statements related to the prospects for the
IMAP Progressive Binding System and peptide substrates. Any
statements contained in this press release that are not statements
of historical fact may be deemed to be forward-looking statements.
Words such as "believes," "anticipates," "plans," "expects,"
"will," and similar expressions are intended to identify
forward-looking statements. There are a number of important factors
that could cause the results of Molecular Devices Corporation to
differ materially from those indicated by these forward-looking
statements, including, among others, risks detailed from time to
time in the Company's SEC reports, including its Annual Report on
Form 10-K for the year ended December 31, 2002 and its quarterly
report on Form 10-Q for the quarter ended September 30, 2003.
Molecular Devices Corporation does not undertake any obligation to
update forward- looking statements. DATASOURCE: Molecular Devices
Corporation CONTACT: Tim Harkness of Molecular Devices Corporation,
+1-408-747-3533 Web site: http://www.moleculardevices.com/
Copyright
Molecular Devices (NASDAQ:MDCC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Molecular Devices (NASDAQ:MDCC)
Historical Stock Chart
From Jul 2023 to Jul 2024